

Pergamon

PII: S0960-894X(96)00287-9

SAR OF 2-BENZYL-4-AMINOPIPERIDINES: CGP 49823, AN ORALLY AND CENTRALLY ACTIVE NON-PEPTIDE NK₁ ANTAGONIST

Silvio Ofner*, Kathleen Hauser, Walter Schilling, Annick Vassout, Siem J. Veenstra Research Department, Pharmaceuticals Division, CIBA-GEIGY AG, CH-4002 Basel, Switzerland Fax: +41 61 696 33 35; e-mail: silvio.ofner@chbs.mhs.ciba.com

Abstract: Novel 2-benzyl-4-aminopiperidines have been shown to be potent and selective antagonists at the NK₁ receptor. Some compounds of this series, e.g. CGP 49823 (2), show CNS activity after oral administration. Copyright © 1996 Elsevier Science Ltd

Substance P (SP), an eleven amino acid peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂) belongs to a family of neuropeptides referred to as the tachykinins¹ and acts via the NK₁ receptor. Studies with peptidic NK₁ receptor agonists and antagonists revealed that Substance P is likely to be associated with a wide range of diseases such as inflammatory processes, e.g. asthma,^{2a} arthritis,^{2b} inflammatory bowel disease,^{2c} with pain,^{2d} emesis^{2e,f} and psychiatric disorders.¹

However, due to the known disadvantages of peptidic receptor ligands, i.e. poor bioavailability and metabolic instability, there was little progress until the first non-peptidic antagonist of SP, CP-96,345 (1) was discovered³ (Chart I). Several reports on non-peptidic low molecular weight antagonists like CP-99,994⁴, RPR-100,893⁵ and SR-140,333⁶ followed.



When we became interested in this field it was known that the minimal structural element of SP which retains biological activity is its C-terminal hexapeptide (3, $IC_{50} = 3 \mu M$, Chart II). Surprisingly, the simple phenylalanine derivative Z-Phe-OBn (4, $IC_{50} = 3 \mu M$), showed a similar affinity for the NK₁ receptor but had antagonist activity.⁷ The assumption that the two aromatic groups in 3 are essential for the affinity towards the NK₁ receptor prompted us to selectively screen compounds from the Ciba compound collection which had at least two aromatic groups five to nine atoms apart. Compound 5 ($IC_{50} = 1.1 \mu M$) is one example of the compounds with moderate affinity thus identified. By comparing 4 and 5 with 3 we argued that two of the aromatic rings in 4 mimic the phenyl groups in the Phe⁷-Phe⁸-moiety lacking a benzyl group. Combining these two features we prepared a series of piperazinones such as 6 ($IC_{50} = 1.5 \mu M$) which is equipotent to 5, but showed higher selectivity for the NK₁ receptor over the NK₂ or NK₃ receptors.

Chart II





One way to avoid the inherent high lipophilicity and low solubility of the piperazinones as 6 was to transpose the lactam nitrogen to the exocyclic position thus gaining a basic center. This led to the 4-amino-piperidine 7 (IC₅₀ = $0.22 \,\mu$ M), a lead compound for extensive structure activity studies.⁷

Herein we wish to report on CGP 49823 (2, Chart I) and the SAR of substituted 4-amino-piperidines as a novel class of highly potent and selective NK_1 receptor antagonists with good CNS activity after oral administration.

The synthesis of the target compounds started with a *Comins*-reaction⁸ in which compound 9 was obtained in 65% yield by treating 4-methoxy-pyridine 8 with benzyl chloroformate and benzylmagnesium chloride in THF at -70 °C (Scheme 1). Sequential hydrogenation afforded a 3.5:1 mixture of the *cis* and *trans* di-substituted piperidines 10 and 11. Selected target compounds were prepared in enantiomerically pure form *via* chiral intermediate (-)-10 which was obtained by Boc-protection and subsequent esterification of racemic 10 with (-)-camphanoyl chloride, chromatographic separation of the diastereomers to afford pure enantiomer 12, subsequent ester hydrolysis and deprotection. The absolute stereochemistry of (-)-10 was confirmed by comparison of the diacetyl derivative (+)-13, derived from (-)-10, with that independently prepared from (R)phenylalanine as starting material.⁹ For SAR comparison, all other compounds have been synthesized in racemic form. Racemic 10 was converted to the azide 14 using a standard reaction sequence.¹⁰ Hydrogenation and a two-step reductive amination with quinoline-4-carbaldehyde to 15 followed by protection / deprotection afforded 16 in 28% overall yield starting from 8.

Scheme 1





Reagents and conditions: (a) PhCH₂OCOCI, PhCH₂MgCI, THF, Et₂O, -70 °C; (b) *i*: H₂, Pd/C (10%), MeOH; *ii*: H₂, RaNi, MeOH; *iii*: separation by flash chromatography; (c) (Boc)₂O, CHCl₃; (d) (-)-camphanoyl chloride, pyridine; (e) separation by flash chromatography; (f) NaOH, MeOH; (g) TFA; (h) MsCl, pyridine; (i) LiN₃, DMF, 80 °C; (k) H₂, Pd/C (10%); (l) *i*: quinoline-4-carbaldehyde, MgSO₄, toluene; *ii*: NaBH₄, MeOH; (m) (CF₃CO)₂O, CH₂Cl₂, NEt₃; (n) HCl, dioxane.

In order to obtain SAR information substituents R were attached at the piperidine nitrogen using derivatization procedures A-D as outlined in Scheme 2. The binding results are summarized in Table 1. IC_{50} values were determined by displacement of ³H-SP from bovine retina membranes.¹¹

Scheme 2



Conditions: A: RCOCl, NEt₃, CH₂Cl₂; B: RCOOH, BOPC, NEt₃; C: R-Br, K₂CO₃, DMF, 60 °C; D: R-Cl, NEt₃, CH₂Cl₂.

Alkyl as well as sulfonyl and alkanoyl substituents at the piperidine nitrogen gave compounds with only weak affinity towards the NK₁ receptor (entries a - c). Comparing entries d - g reveals that substitution at the benzoyl group is necessary and is best at position 3. Disubstitution further enhances the binding affinity if the aromatic substituents are in 3,5 position and are either methyl, halogen or bistrifluoromethyl (entries i - k), but not phenolic derivatives (entries 1 - m). Condensed aromatic groups like naphthoyl (entries n - o) do not fit as well to the binding site at the receptor.

Entry	R	conditions*)	compound	IC ₅₀ [nM] ¹¹
a	3,5-bis(trifluoromethyl)benzyl	D	18	880
b	3,5-bistrifluoromethylphenyl-sulfonyl	С	19	> 10'000
с	phenyl acetyl	Α	20	3300
đ	benzoyl	А	21	1380
e	2-chlorobenzoyl	В	22	1040
f	3-chlorobenzoyl	Α	23	54
g	4-chlorobenzoyl	В	24	1370
h	3,5-dichlorobenzoyl	Α	25	26
i	3,5-dimethylbenzoyl		(+)-2 ^{13**)}	12
j	3,5-dibromobenzoyl	Α	26	24
k	3,5-bis(trifluoromethyl)benzoyl	В	27	17
1	3,5-dimethoxybenzoyl	В	28	92
m	3,5-dihydroxybenzoyl	в	29	520
n	1-naphthoyl	Α	30	110
0	2-naphthoyl	Α	31	700

Table 1

*) see Scheme 2 **) CGP 49823

The substituents at the exocyclic amino function were explored following a reaction sequence outlined in Scheme 3.¹² The results are summarized in Table 2. At least one small substituent at the exocyclic nitrogen is necessary for good *in vitro* activity, although no clear requirements as to the size of the substituent and/or the positioning of functional groups can be read from entries a - f. The distance and/or the bulk of an aromatic group from the amino piperidine moiety seems to be crucial, as is exemplified with entries g - j. Good to excellent binding affinities can also be obtained with an amide or urea functionality, but as these compounds lack a basic nitrogen they are less water soluble (entries k - m). Enhancing the water solubility by introducing oxygen functionalities retains *in vitro* activity (entries n - o), but these compounds suffer from poor bioavailability (*vide infra*). Double substitution at the exocyclic amino group is not favourable (entries p - q).



Reagents and conditions: (a) TFA; (b) $3,5-X_2C_6H_3COCI$, NEt₃, CH_2Cl_2 or $3,5-X_2C_6H_3COCI$, NaHCO₃, toluene, water, 0 °C; (c) H₂, Pd/C (10%), MeOH; (d) A: Ac₂O, NEt₃, CH_2Cl_2 ; B: i: BrCH₂COOMe, NEt₃, THF; ii: MeOH, NH₃; C: i: BocNHCH₂COOH, BOPC, NEt₃, CH₂Cl₂; ii: TFA; D: Cl(CH₂)₃NMe₂, K₂CO₃, CH₃CN, 80 °C; E: iPtNCO, toluene, DMAP; F: BnBr, NEt₃, THF; G: i: RCHO, MgSO₄, toluene; ii: NaBH₄, MeOH or NaCNBH₃, AcOH, MeOH; H: RCOOH, BOPC, NEt₃, CH₂Cl₂; I: PhCH₂COCI, NaHCO₃, toluene, water, 0 °C.

	Table 2					
litions	(see scheme 3)	compound	x	R ₁	R ₂	IC ₅₀ [nM] ¹¹
		(-)-34	CF ₃	Н	Н	180
	Α	(+)-35	CF ₃	acetyl	Н	19
	B	(+)- 36 ¹⁴	CF ₃	carbamoylmethyl	н	10
	С	(+)-37	CF ₃	2-amino-acetyl	Н	62
	D	3815	CF ₃	3-dimethylamino- propyloxycarbonyl	Н	11
	Ε	(+)-39	CF ₃	isopropylcarbamoyl	н	20
	F	(+)-40 ¹³	CH	benzyl	Н	220
	G	41 ¹³	CH ₃	pyridin-4-ylmethyl	Н	210
	G	42 ¹³	CH	quinoline-3-ylmethyl	Н	30
	G	43 ¹³	CH ₃	quinoline-2-ylmethyl	Н	19
	H	44	CĽ	quinoline-4-carbonyl	Н	10
	I	45	CI	2-phenyl-acetyl	н	60

phenylcarbamoyl

2-(3,5-dimethoxy-

quinoline-4-ylmethyl

quinoline-4-ylmethyl

phenyl)-acetyl

carbonyl

2-hydroxy-quinoline-4-

Н

H

Η

CH₁

COCF₃

72

9

12

390

600

Entry

a b с d e f g h i í k 1

m

n

0

p

q

con

PhNCO, 100°

Η

2-(3,5-dimethoxy-phenyl)-

acetic acid, DCC, THF

25, NaH, DME, MeI

We then investigated the absolute stereochemistry required for high affinity NK₁ binding. We found that the (2R,4S)-stereoisomer (+)-2 (CGP 49823, Chart I) is the most potent of the diastereoisomers (Table 3). Hence the stereochemistry at the 2-position does not correspond to the stereochemistry of the Phe⁷ benzyl side chain in 3 as was initially anticipated. The remarkably good overlap of a minimal energy conformation with one of CP-96,345 1, suggests that this compound binds to the same antagonist binding site of the NK₁ receptor as does 1. Confirmation was obtained by competitive binding studies of CP-96,345 (IC₅₀ = 0.79 nM; N_H = 0.99) with ³H₂-CGP 49823.¹⁶ This site in turn is not directly involved in the binding of Substance P¹⁷. Next, the *in vitro* functional activities, receptor selectivities and oral activities of CGP 49823 along with some of the more interesting compounds and, for comparison purposes, of CP-96,345 were evaluated (Table 3).

Cl

CF₃

CH₁

CL

Cl

46

48

49

17h

(+)-47

		IC ₅₀	IC ₅₀				% Inhib. (2 h)
compound	configuration .	PI turnover ^a	NK ₁ ^b	NK2 ^c	NK3d	NK ₁ (g) ^e	thumping ^f
(+)-2	2R , 4S	12	13	2790	2650	55	34
(-)-2	2S , 4R	150	130	(5%)	na	690	548
(-)- 50 ^h	2R , 4R	nt	540	nt	nt	nt	20 ⁱ
(+)-50 ^h	2S , 4S	nt	220	nt	nt	nt	nt
42	2R* , 4S *	210	30	(22%)	10'000	70	21
44	2R* , 4S *	24	10	4500	3300	48	66
(+)-47	2R , 4S	nt	9	(28%)	450	10	24
(±)-CP-96,345	(1)	9	10	(24%)	na	16	61 ^j

Table 3

⁴ Inhibition of substance P induced phosphatidyl inositol turnover in human U-373 cells in nM units (see Ref. [18]). ^b ³H-SP radioligand binding, bovine retina in nM units (see Ref. [11]). ° 125I-NKA radioligand binding, bovine bladder in nM units or % inhibition at 1 µM (see Ref. [19]). d 1251-Eledoisin radioligand binding, gerbil cortex in nM units (see Ref. [20]). e see Ref. [21]. I Inhibition of thumping behaviour in gerbils induced by i.c.v. administration of SP-methyl ester 2 hours after p.o. administration of 30 mg /kg of the compound; values given in % (100% = full inhibition; see Ref [22]). 8 300 mg /kg p.o.. h cis isomer of 2. 60 mg/kg i.p., 300 mg/kg p.o.. na = no activity; nt = not tested.

The relevance of the inhibition of the thumping behaviour in gerbils for humans is illustrated by the good correlation of the binding to the NK_1 receptor in gerbils with the inhibition of the PI turnover in human cells (see table 3).

In conclusion, the novel 2-benzyl-4-aminopiperidines are highly potent and selective antagonists at the NK1 receptor. The piperidine ring system described herein provides a scaffold for extensive SAR studies. Some of the compounds show central activity after oral administration in antagonizing the effects of Substance P methyl ester.

Acknowledgements : We wish to thank V. Bandelier, U. Bützberger, J. Heid, A. Koblet, C. Riegert, M. Roggwiller, M. Schaub and P. Schmid for their skillful technical assistance and our colleagues from the Analytical Department for providing spectral and analytical data.

References and Notes

- (1) Otsuka, M.; Yoshioka, K. Physiological Reviews 1993, 73, 228.
- (2) (a) Barnes, P.; Belvisi, M.; Rogers, D. Trends Pharmacol. Sci. 1993, 11, 185. (b) Lotz, M.; Carson, D.A.; Vaughan, J.H. Science 1987, 235, 893. (c) Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. J. Auton. Pharmacol. 1993, 13, 23. (d) Laird, J. M. A.; Hargreaves, R. J.; Hill, R. G. Br. J. Pharmacol. 1993, 109, 259. (e) Tattersall, F.D.; Rycroft, W.; Hargreaves, R.J.; Hill, R.G. Eur. J. Pharmacol. 1993, 250, R5-R6. (f) Davison, J.S.; Oland, L.; Boissonade, F. Gastroenterology 1995, 108 (4 Suppl.), A589.
- (3) Snider, R.M.; Constantine, J.W.; Lowe III, J.A.; Longo, K.P.; Lebel, W.S.; Woody, H.A.; Drozda, S.E.; Desai, M.C.; Vinick. F.J.; Spencer, R.W.; Hess, H.-J. Science 1991, 251, 435.
- (4) Desai, M.C.; Lefkowitz, S.L.; Thadeio, P.F.; Longo, K.P.; Snider, R.M. J. Med. Chem. 1992, 35, 4911.
- (5) Tabart, M.; Peyronel, J-F. Bioorg. Med. Chem. Lett. 1994, 4, 673.
- (6) Oury-Donat, F.; Lefevre, I. A.; Thurneyssen, O.; Gauthier, T.; Bordey, A.; Feltz, P.; Emonds-Alt, X.; Le Fur, G.; Soubrie, P. J. Neurochem. 1994, 62, 1399.
- (7) Schilling, W.; Bittiger, H.; Brugger, F.; Criscione, L.; Hauser, K.; Ofner, S.; Olpe, H.-R.; Vassout, A.; Veenstra, S. "Approaches Towards the Design and Synthesis of Nonpeptidic Substance-P Antagonists", in *Perspectives in Medicinal Chemistry*, pp. 207-220, Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Ed.; Verlag Helvetica Chimica Acta, Basel, 1993.
- (8) Comins, D.L.; Goehring, R.R.; Joseph, S.P.; O'Connor, S. J. Org. Chem. 1990, 55, 2574.
- (9) Schilling, W.; Ofner, S.; Veenstra, S. J. Europ. Pat. EP 532456 (1990).
 (-)-10: oil, ¹H-NMR (500 MHz, CDCl₃) 7.35 7.20 (m, 5H), 3.63 (tt, J=11.5 and 4.4 Hz, 1H), 3.06 (ddd, J=12.5, 4.4 and 2.4 Hz, 1H), 2.78 2.71 (m, 2H), 2.69 2.62 (m, 1H), 2.54 (td, J=12.5 and 2.4 Hz, 1H), 2.02 (dtd, J=11.5, 4.5 and 2.4 Hz, 1H), 1.93 (ddq, J=12, 4.5 and 2.4 Hz, 1H), 1.45 (b, 2H), 1.38 (qd, J≈11.5 and 4.4 Hz, 1H), 1.16 (q, J≈11.5 Hz, 1H); [α]_D²⁰ = -11.8° (c = 0.5, MeOH). (+)-13: m.p. 139° C.; [α]_D²⁵ = +20.2° (c = 0.8, MeOH).
- (10) Azidolysis to 14 was accompanied by elimination to an unsaturated piperidin derivative (3:1 w/w) according to ¹H-NMR. The mixture could only be separated chromatographically after hydrogenolysis.
- (11) For experimental details see: Bittiger, H. and Heid, J. "The retina, a part of the central nervous system with a very high density of ³H-Substance P binding sites", in Substance P Dublin, pp 198-199, Skrabanek, P.; Powell, D., Ed.; Boole Press Ltd., Dublin, 1983.
- (12) Intermediates 33 can also be prepared according to Ref. [9].
- (13) Prepared according to Ref. [9];
 (+)-2: m.p.: 143° C.; ¹H-NMR (300 MHz, CDCl₃) 8.89 (d, J=5 Hz, 1H), 8.16 (d, J=8 Hz, 1H), 8.09 (d, J=8 Hz, 1H), 7.73 (t, J=8 Hz, 1H), 7.60 (t, J=8 Hz, 1H), 7.46 (d, J=5 Hz, 1H), 7.35 7.20 (m, 4H), 7.04 6.74 (m, 3H), 6.42 (b, 1H), 5.35 5.20 (m, 0.4H), 4.89 4.75 (m, 0.6H), 4.40 4.20 (m, 2H), 4.15 4.00 (m, 0.6H), 3.75 3.60 (m, 0.4H), 3.30 2.90 (m, 3.4H), 2.76 2.60 (m, 0.6H), 2.28 (b, 2.4H, minor rotamer), 2.22 (b, 3.6H, major rotamer), 2.1 1.2 (m, 5H) ;[G]_D²⁰ = +27.8 ± 0.5° (c = 2.08, MeOH).
- (14) Dialkylation was also observed (mono : di = 2:1).
- (15) The major product resulted from CO_2 insertion.
- (16) ${}^{3}\text{H}_{2}$ -CGP 49823 ((2R,4S)-2-(3,5-Bis- ${}^{3}\text{H-benzyl})$ -1-(3,5-dimethylbenzoyl)-N-(4-chinolylmethyl)-4-piperidinamin) radioligand binding, bovine retina; CGP 49823: IC₅₀ = 1.56 nM; N_H = 1.13)
- (17) (a) Gether, U.; Nilsson, L.; Lowe III, J.A.; Schwartz, T.W. J. Biol. Chem. 1994, 269, 23959. (b) Mills, S.G.; MacCoss, M.; Underwood, D.; Shah, S.K.; Finke, P.E.; Miller, D.J.; Budhu, R.J.; Cascieri, M.A.; Sadowski, S.; Strader, C.D. Bioorg. Med. Chem. Lett. 1995, 5, 1345.
- (18) Heuillet, E.; Ménager, J.; Fardin, V.; Flamand, O.; Bock, M.; Garret, C.; Crespo, A.; Fallourd, A.M.; Doble, A. J. Neurochem. 1993, 60, 868.
- (19) Hauser, K.; Heid, J.; Bittiger, H. Regul. Pept. 1988, 22, 83.
- (20) Torrens, Y.; Lavielle, S.; Chassaing, G.; Marquet, A.; Glowinski, J.; Beaujouan, J.C. Eur. J. Pharmacol. 1984, 102, 381.
- (21) NK₁(g): ³H-SP radioligand binding, gerbil midbrain in nM units.
- (22) (a) Vassout, A.; Schaub, M.; Hauser, K.; Schilling, W. "Substance P induces hindlimb thumping behaviour in gerbils" Conference poster: Substance P and Related Peptides: Cellular and Molecular Physiology, Worchester, Mass. 1990. (b) Vassout, A.; Schaub, M.; Gentsch, C.; Ofner, S.; Schilling, W.; Veenstra, S. Neuropeptides 1994, 26, Suppl 1, 38.